Concord Biotech Limited CC-Mar24.pdf · 2024-05-28
Yes. Hi. Good evening. So I had a couple of questions. One was, as we see introduction of new therapies like oncology and anti-infective share of revenue going higher. Are these gross margin dilutives compared to immunosuppression?
Okay. And secondly, amongst your key products like Tacrolimus and Everolimus, there are different dosage forms that are going off until next year or year after. So just wanted to understand how big are these opportunities for you and can these products add materially to your API revenue and hence the guidance of 25% CAGR?